SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. The Company also announced that Leslie Trigg has been appointed Chair of the Board of Directors in addition to her ongoing role as President and Chief Executive Officer.
Recent Highlights
- Recorded net revenue of $28.2 million in the fourth quarter of 2021, a 63.2% increase compared to $17.2 million in the fourth quarter of 2020, and $102.6 million for the full year of 2021, representing an increase of 105.5% compared to $49.9 million for 2020
- Achieved gross margin for the fourth quarter of 2021 of 11.8%, compared to 2.4% in the fourth quarter of 2020
- Signed agreements with 7 of the 8 largest national health systems and one-third of the largest 100 regional health systems
- Granted 510(k) clearance from the Food and Drug Administration (FDA) for Tablo® Hemodialysis System cartridge, enabling full production in Mexico
- Received the first-ever approval for the Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) program from the Centers for Medicare & Medicaid Services (CMS), which deemed Tablo® a substantial clinical improvement over the incumbent home hemodialysis device
- Released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s ESG-related programs, priorities, goals, and performance
- Leslie Trigg appointed Chair in addition to her ongoing role as Chief Executive Officer. Former Chairman D. Keith Grossman continues to serve on the board and has been appointed Lead Independent Director
“Our entire team contributed to an exceptional 2021, driving record revenue growth, meaningful progress toward our long-term gross margin goal and excellent visibility into 2022,” said Leslie Trigg, Chair and Chief Executive Officer. “Our established relationships with 7 of the 8 largest national health systems and one-third of the largest 100 regional health systems puts us in a strong position for growth this year in both the acute and home settings.”
“On behalf of the Outset Board of Directors, I am pleased to announce Leslie’s appointment to the additional role of Board Chair,” said D. Keith Grossman, Lead Independent Director. “We look forward to continuing to support Leslie and the entire team as Outset continues to transform the dialysis industry.”
Fourth Quarter 2021 Financial Results
Revenue for the fourth quarter of 2021 was $28.2 million, representing an increase of 63.2% compared to $17.2 million in the fourth quarter of 2020. Product revenue for the fourth quarter of 2021 was $23.7 million, representing an increase of 79.5% compared to $13.2 million in the fourth quarter of 2020. Service and other revenue for the fourth quarter of 2021 was $4.5 million, representing an increase of 10.6% compared to $4.1 million in the fourth quarter of 2020.
Total gross profit for the fourth quarter of 2021 was $3.3 million, compared to a gross loss of $0.4 million for the fourth quarter of 2020. Total gross margin for the fourth quarter of 2021 was 11.8%, compared to 2.4% in the fourth quarter of 2020. On a non-GAAP basis, gross margin for the fourth quarter of 2021 improved to 12% from 2.8% in the fourth quarter of 2020. Product gross profit for the fourth quarter of 2021 was $2.2 million, compared to ($1.7) million of product gross loss in the fourth quarter of 2020. Product gross margin for the fourth quarter of 2021 was 9.3%, compared to (13.2)% in the fourth quarter of 2020. Service and other gross profit for the fourth quarter of 2021 was $1.1 million, compared to $2.2 million of service and other gross profit in the fourth quarter of 2020. Service and other gross margin for the fourth quarter of 2021 was 25.1%, compared to 53.0% in the fourth quarter of 2020.
Operating expenses for the fourth quarter of 2021 were $44.1 million, including research and development (R&D) expenses of $11.4 million, sales and marketing (S&M) expenses of $23.0 million, and general and administrative (G&A) expenses of $9.7 million. This compared to operating expenses of $32.0 million, including R&D expenses of $7.8 million, S&M expenses of $15.2 million, and G&A expenses of $9.1 million in the fourth quarter of 2020.
Excluding stock-based compensation expense, non-GAAP operating expenses for the fourth quarter of 2021 were $39.4 million, including R&D expenses of $10.2 million, S&M expenses of $21.1 million, and G&A expenses of $8.1 million.
Fourth quarter 2021 net loss was ($41.2) million, or ($0.87) per share, compared to net loss of ($32.0) million, or ($0.75) per share, for the same period in 2020. On a non-GAAP basis, net loss for the fourth quarter of 2021 was ($36.4) million, or ($0.77) per share, compared to non-GAAP net loss of ($25.8) million, or ($0.60) per share for the same period in 2020.
Full Year 2021 Financial Results
Revenue for the full year of 2021 was $102.6 million, representing an increase of 105.5% compared to $49.9 million for 2020. Product revenue for the full year of 2021 was $84.3 million, representing an increase of 112.8% compared to $39.6 million for 2020. Service and other revenue for the full year of 2021 was $18.3 million, representing an increase of 77.2% compared to $10.3 million for 2020.
Total gross profit for the full year of 2021 was $7.6 million, compared to a gross loss of ($13.0) million for 2020. Total gross margin for the full year of 2021 was 7.4%, compared to (26.1)% in 2020. Product gross loss for the full year of 2021 was ($0.3) million, compared to ($17.4) million of product gross loss in 2020. Product gross margin for the full year of 2021 was (0.4)%, compared to (44.0)% in 2020. Service and other gross profit for the full year of 2021 was $7.9 million, compared to $4.4 million of service and other gross profit in 2020. Service and other gross margin for the full year of 2021 was 43.4%, compared to 42.5% in 2020.
Operating expenses for the full year of 2021 were $138.1 million, including R&D expenses of $36.7 million, S&M expenses of $65.1 million, and G&A expenses of $36.3 million. This compared to operating expenses of $104.4 million, including R&D expenses of $28.9 million, S&M expenses of $45.1 million, and G&A expenses of $30.5 million for 2020.
Excluding stock-based compensation expense, non-GAAP operating expenses for the full year of 2021 were $121.0 million, including R&D expenses of $32.9 million, S&M expenses of $59.2 million, and G&A expenses of $28.8 million.
Full year 2021 net loss attributable to common stockholders was ($131.9) million, or ($2.89) per share, compared to a net loss attributable to common stockholders of ($79.3) million, or ($4.85) per share, for 2020. On a non-GAAP basis, net loss for the full year of 2021 was ($114.5) million, or ($2.51) per share, compared to a non-GAAP net loss of ($57.9) million, or ($3.54) per share for 2020.
Total cash, including restricted cash, cash equivalents and short-term investments, was $372.8 million as of December 31, 2021.
Full Year 2022 Financial Guidance
Outset projects revenue for the full year 2022 to range from $142 million to $150 million, which represents approximately 38% to 46% growth over the Company’s fiscal year 2021 revenue.
Webcast and Conference Call Details
Outset will host a conference call today, February 16, 2022, at 2:00 p.m. PT / 5:00 p.m. ET to discuss its fourth quarter and full year 2021 financial results. The dial-in numbers are (833) 614-1409 for domestic callers and (914) 987-7130 for international callers. The conference ID is 6892802. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.outsetmedical.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
The Company may report non‐GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, basic and diluted net income/loss per share, other income/loss, and cash flows. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company’s financial measures under GAAP include stock-based compensation expense, as listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. Management has excluded the effects of this non-cash expense item in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance and period-to-period comparisons. There are limitations related to the use of non-GAAP financial measures because they are not prepared in accordance with GAAP, may exclude significant expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non‐GAAP results are presented in the Appendix A of this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s possible or assumed future results of operations and financial position, including expectations regarding projected revenues (including sales into the home market and such sales as a percentage of revenues), gross margin, operating expenses, capital expenditures, profitability and outlook; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo; continued execution of the Company’s initiatives designed to reduce the cost of producing and shipping Tablo devices and its ability to achieve projected cost reductions at the level or within the timeframe estimated; the Company’s expectations with respect to anticipated benefits of the TPNIES approval, as well as the Company’s expectations regarding the continuing impact of the COVID-19 pandemic on the Company and its operations as well as the impact on its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Outset’s public filings with the Securities and Exchange Commission, including Outset’s latest annual and quarterly reports. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Outset Medical, Inc. |
||||||||||||||||||||
Condensed Statements of Operations |
||||||||||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||||||
(unaudited) |
||||||||||||||||||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue |
|
$ |
23,650 |
|
|
|
$ |
13,177 |
|
|
|
$ |
84,312 |
|
|
|
$ |
39,612 |
|
|
Service and other revenue |
|
|
4,502 |
|
|
|
|
4,070 |
|
|
|
|
18,290 |
|
|
|
|
10,323 |
|
|
Total revenue |
|
|
28,152 |
|
|
|
|
17,247 |
|
|
|
|
102,602 |
|
|
|
|
49,935 |
|
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of product revenue (2) |
|
|
21,459 |
|
|
|
|
14,917 |
|
|
|
|
84,639 |
|
|
|
|
57,035 |
|
|
Cost of service and other revenue |
|
|
3,372 |
|
|
|
|
1,913 |
|
|
|
|
10,355 |
|
|
|
|
5,937 |
|
|
Total cost of revenue |
|
|
24,831 |
|
|
|
|
16,830 |
|
|
|
|
94,994 |
|
|
|
|
62,972 |
|
|
Gross profit (1) |
|
|
3,321 |
|
|
|
|
417 |
|
|
|
|
7,608 |
|
|
|
|
(13,037 |
) |
|
Gross margin (1) |
|
|
11.8 |
|
% |
|
|
2.4 |
|
% |
|
|
7.4 |
|
% |
|
|
(26.1 |
) |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development (2) |
|
|
11,410 |
|
|
|
|
7,784 |
|
|
|
|
36,741 |
|
|
|
|
28,850 |
|
|
Sales and marketing (2) |
|
|
22,991 |
|
|
|
|
15,198 |
|
|
|
|
65,070 |
|
|
|
|
45,068 |
|
|
General and administrative (2) |
|
|
9,719 |
|
|
|
|
9,050 |
|
|
|
|
36,316 |
|
|
|
|
30,512 |
|
|
Total operating expenses |
|
|
44,120 |
|
|
|
|
32,032 |
|
|
|
|
138,127 |
|
|
|
|
104,430 |
|
|
Loss from operations |
|
|
(40,799 |
) |
|
|
|
(31,615 |
) |
|
|
|
(130,519 |
) |
|
|
|
(117,467 |
) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income and other income, net |
|
|
123 |
|
|
|
|
2 |
|
|
|
|
498 |
|
|
|
|
526 |
|
|
Interest expense |
|
|
(431 |
) |
|
|
|
(430 |
) |
|
|
|
(1,715 |
) |
|
|
|
(2,891 |
) |
|
Change in fair value of redeemable convertible preferred stock warrant liability |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(93 |
) |
|
Loss on extinguishment of term loan |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(1,567 |
) |
|
Loss before provision for income taxes |
|
|
(41,107 |
) |
|
|
|
(32,043 |
) |
|
|
|
(131,736 |
) |
|
|
|
(121,492 |
) |
|
Provision for income taxes |
|
|
125 |
|
|
|
|
— |
|
|
|
|
199 |
|
|
|
|
— |
|
|
Net loss |
|
$ |
(41,232 |
) |
|
|
$ |
(32,043 |
) |
|
|
$ |
(131,935 |
) |
|
|
$ |
(121,492 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss attributable to common stockholders, basic and diluted (3) |
|
$ |
(41,232 |
) |
|
|
$ |
(32,043 |
) |
|
|
$ |
(131,935 |
) |
|
|
$ |
(79,324 |
) |
|
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.87 |
) |
|
|
$ |
(0.75 |
) |
|
|
$ |
(2.89 |
) |
|
|
$ |
(4.85 |
) |
|
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted |
|
|
47,169 |
|
|
|
|
42,715 |
|
|
|
|
45,589 |
|
|
|
|
16,358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(1) Gross profit and gross margin by source consisted of the following: |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
|
|||||||||||||
|
|
December 31, |
|
|
December 31, |
|
|
|||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue |
|
$ |
2,191 |
|
|
|
$ |
(1,740 |
) |
|
|
$ |
(327 |
) |
|
|
$ |
(17,423 |
) |
|
Service and other revenue |
|
|
1,130 |
|
|
|
|
2,157 |
|
|
|
|
7,935 |
|
|
|
|
4,386 |
|
|
Total gross profit |
|
$ |
3,321 |
|
|
|
$ |
417 |
|
|
|
$ |
7,608 |
|
|
|
$ |
(13,037 |
) |
|
Gross margin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenue |
|
|
9.3 |
|
% |
|
|
(13.2 |
) |
% |
|
|
(0.4 |
) |
% |
|
|
(44.0 |
) |
% |
Service and other revenue |
|
|
25.1 |
|
% |
|
|
53.0 |
|
% |
|
|
43.4 |
|
% |
|
|
42.5 |
|
% |
Total gross margin |
|
|
11.8 |
|
% |
|
|
2.4 |
|
% |
|
|
7.4 |
|
% |
|
|
(26.1 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(2) Include stock-based compensation expenses as follows: |
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
Cost of revenue |
|
$ |
68 |
|
|
|
$ |
74 |
|
|
|
$ |
269 |
|
|
|
$ |
255 |
|
|
Research and development |
|
|
1,241 |
|
|
|
|
1,289 |
|
|
|
|
3,809 |
|
|
|
|
4,615 |
|
|
Sales and marketing |
|
|
1,896 |
|
|
|
|
1,595 |
|
|
|
|
5,897 |
|
|
|
|
4,423 |
|
|
General and administrative |
|
|
1,587 |
|
|
|
|
3,310 |
|
|
|
|
7,470 |
|
|
|
|
12,146 |
|
|
Total stock-based compensation expenses |
|
$ |
4,792 |
|
|
|
$ |
6,268 |
|
|
|
$ |
17,445 |
|
|
|
$ |
21,439 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
(3) A reconciliation of the net loss to net loss attributable to common stockholders is as follows: |
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
Net loss |
|
$ |
(41,232 |
) |
|
|
$ |
(32,043 |
) |
|
|
$ |
(131,935 |
) |
|
|
$ |
(121,492 |
) |
|
Adjustment to redemption value on redeemable convertible preferred stock |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(362 |
) |
|
Deemed dividend on settlement of accrued dividend* |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
42,530 |
|
|
Net loss attributable to common stockholders, basic and diluted |
|
$ |
(41,232 |
) |
|
|
$ |
(32,043 |
) |
|
|
$ |
(131,935 |
) |
|
|
$ |
(79,324 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
* Deemed dividend on settlement of accrued dividend arose as a result of the terms and conditions associated with the Company's redeemable convertible preferred stock outstanding prior to the Company's initial public offering ("IPO"). These terms and conditions were described in the Company's previous SEC filings, including the 424(b) prospectus filed on September 16, 2020 in connection with the IPO. |
|
|
||||||||||||||||||
|
|
|
||||||||||||||||||
Outset Medical, Inc. |
||||||||
Condensed Balance Sheets |
||||||||
(in thousands, except per share amounts) |
||||||||
|
|
December 31, |
|
|
December 31, |
|
||
|
|
2021 |
|
|
2020 |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
182,348 |
|
|
$ |
294,972 |
|
Short-term investments |
|
|
157,140 |
|
|
|
19,898 |
|
Accounts receivable, net |
|
|
25,600 |
|
|
|
6,468 |
|
Inventories |
|
|
39,185 |
|
|
|
18,384 |
|
Prepaid expenses and other current assets |
|
|
5,529 |
|
|
|
6,189 |
|
Total current assets |
|
|
409,802 |
|
|
|
345,911 |
|
Restricted cash |
|
|
33,311 |
|
|
|
33,311 |
|
Property and equipment, net |
|
|
12,964 |
|
|
|
14,998 |
|
Operating lease right-of-use assets |
|
|
7,231 |
|
|
|
8,253 |
|
Other assets |
|
|
156 |
|
|
|
1,356 |
|
Total assets |
|
$ |
463,464 |
|
|
$ |
403,829 |
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,763 |
|
|
$ |
4,948 |
|
Accrued compensation and related benefits |
|
|
24,948 |
|
|
|
16,845 |
|
Accrued expenses and other current liabilities |
|
|
13,789 |
|
|
|
7,903 |
|
Accrued warranty liability |
|
|
3,704 |
|
|
|
2,913 |
|
Deferred revenue, current |
|
|
6,340 |
|
|
|
3,201 |
|
Operating lease liabilities, current |
|
|
1,151 |
|
|
|
882 |
|
Total current liabilities |
|
|
51,695 |
|
|
|
36,692 |
|
Accrued interest, noncurrent |
|
|
721 |
|
|
|
240 |
|
Deferred revenue, noncurrent |
|
|
312 |
|
|
|
570 |
|
Operating lease liabilities, noncurrent |
|
|
6,893 |
|
|
|
8,044 |
|
Term loan, noncurrent |
|
|
29,762 |
|
|
|
29,674 |
|
Total liabilities |
|
|
89,383 |
|
|
|
75,220 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2021 and 2020 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2021 and 2020; 47,241 and 42,722 shares issued and outstanding as of December 31, 2021 and 2020, respectively |
|
|
47 |
|
|
|
43 |
|
Additional paid-in capital |
|
|
1,000,212 |
|
|
|
822,624 |
|
Accumulated other comprehensive (loss) income |
|
|
(184 |
) |
|
|
1 |
|
Accumulated deficit |
|
|
(625,994 |
) |
|
|
(494,059 |
) |
Total stockholders' equity |
|
|
374,081 |
|
|
|
328,609 |
|
Total liabilities and stockholders' equity |
|
$ |
463,464 |
|
|
$ |
403,829 |
|
Outset Medical, Inc. |
||||||||
Condensed Statements of Cash Flows |
||||||||
(in thousands) |
||||||||
(unaudited) |
||||||||
|
|
Years Ended December 31, |
||||||
|
|
2021 |
|
2020 |
||||
Net cash used in operating activities |
|
$ |
(130,264 |
) |
|
$ |
(99,015 |
) |
Net cash provided by (used in) investing activities |
|
|
(142,507 |
) |
|
|
3,947 |
|
Net cash provided by financing activities |
|
|
160,147 |
|
|
|
385,682 |
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
(112,624 |
) |
|
|
290,614 |
|
Cash, cash equivalents and restricted cash at beginning of the period |
|
|
328,283 |
|
|
|
37,669 |
|
Cash, cash equivalents and restricted cash at end of the period (1) |
|
$ |
215,659 |
|
|
$ |
328,283 |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed balance sheets that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): |
|
|||||||
|
|
|||||||
|
|
December 31, |
||||||
|
|
2021 |
|
2020 |
||||
Cash and cash equivalents |
|
$ |
182,348 |
|
|
$ |
294,972 |
|
Restricted cash |
|
|
33,311 |
|
|
|
33,311 |
|
Total cash, cash equivalents and restricted cash* |
|
$ |
215,659 |
|
|
$ |
328,283 |
|
|
|
|
|
|
|
|
||
* The total cash, including restricted cash, cash equivalents and investment securities as of December 31, 2021 was $372.8 million; compared to $348.2 million as of December 31, 2020. |
|
|||||||
|
|
|||||||
Appendix A |
||||||||||||||||||||
Outset Medical, Inc. |
||||||||||||||||||||
Results of Operations – Non-GAAP |
||||||||||||||||||||
(in thousands, except per share amounts) |
||||||||||||||||||||
(unaudited) |
||||||||||||||||||||
Reconciliation between GAAP and non-GAAP net loss per share attributable to common stockholders: |
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
|
|||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
GAAP net loss per share to common stockholders, diluted |
|
$ |
(0.87 |
) |
|
|
$ |
(0.75 |
) |
|
|
$ |
(2.89 |
) |
|
|
$ |
(4.85 |
) |
|
Stock-based compensation expense |
|
|
0.10 |
|
|
|
|
0.15 |
|
|
|
|
0.38 |
|
|
|
|
1.31 |
|
|
Non-GAAP net loss per share to common stockholders, diluted |
|
$ |
(0.77 |
) |
|
|
$ |
(0.60 |
) |
|
|
$ |
(2.51 |
) |
|
|
$ |
(3.54 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation between GAAP and non-GAAP net loss attributable to common stockholders: |
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
GAAP net loss attributable to common stockholders, diluted |
|
$ |
(41,232 |
) |
|
|
$ |
(32,043 |
) |
|
|
$ |
(131,935 |
) |
|
|
$ |
(79,324 |
) |
|
Stock-based compensation expense |
|
|
4,792 |
|
|
|
|
6,268 |
|
|
|
|
17,445 |
|
|
|
|
21,439 |
|
|
Non-GAAP net loss per share attributable to common stockholders, diluted |
|
$ |
(36,440 |
) |
|
|
$ |
(25,775 |
) |
|
|
$ |
(114,490 |
) |
|
|
$ |
(57,885 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reconciliation between GAAP and non-GAAP results of operations: |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Years Ended |
|
||||||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||||||
GAAP gross profit |
|
$ |
3,321 |
|
|
|
$ |
417 |
|
|
|
$ |
7,608 |
|
|
|
$ |
(13,037 |
) |
|
Stock-based compensation expense |
|
|
68 |
|
|
|
|
74 |
|
|
|
|
269 |
|
|
|
|
255 |
|
|
Non-GAAP gross profit |
|
$ |
3,389 |
|
|
|
$ |
491 |
|
|
|
$ |
7,877 |
|
|
|
$ |
(12,782 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP gross margin |
|
|
11.8 |
|
% |
|
|
2.4 |
|
% |
|
|
7.4 |
|
% |
|
|
(26.1 |
) |
% |
Stock-based compensation expense |
|
|
0.2 |
|
|
|
|
0.4 |
|
|
|
|
0.3 |
|
|
|
|
0.5 |
|
|
Non-GAAP gross margin |
|
|
12.0 |
|
% |
|
|
2.8 |
|
% |
|
|
7.7 |
|
% |
|
|
(25.6 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP research and development expense |
|
$ |
11,410 |
|
|
|
$ |
7,784 |
|
|
|
$ |
36,741 |
|
|
|
$ |
28,850 |
|
|
Stock-based compensation expense |
|
|
(1,241 |
) |
|
|
|
(1,289 |
) |
|
|
|
(3,809 |
) |
|
|
|
(4,615 |
) |
|
Non-GAAP research and development expense |
|
$ |
10,169 |
|
|
|
$ |
6,495 |
|
|
|
$ |
32,932 |
|
|
|
$ |
24,235 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP sales and marketing expense |
|
$ |
22,991 |
|
|
|
$ |
15,198 |
|
|
|
$ |
65,070 |
|
|
|
$ |
45,068 |
|
|
Stock-based compensation expense |
|
|
(1,896 |
) |
|
|
|
(1,595 |
) |
|
|
|
(5,897 |
) |
|
|
|
(4,423 |
) |
|
Non-GAAP sales and marketing expense |
|
$ |
21,095 |
|
|
|
$ |
13,603 |
|
|
|
$ |
59,173 |
|
|
|
$ |
40,645 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP general and administrative expense |
|
$ |
9,719 |
|
|
|
$ |
9,050 |
|
|
|
$ |
36,316 |
|
|
|
$ |
30,512 |
|
|
Stock-based compensation expense |
|
|
(1,587 |
) |
|
|
|
(3,310 |
) |
|
|
|
(7,470 |
) |
|
|
|
(12,146 |
) |
|
Non-GAAP general and administrative expense |
|
$ |
8,132 |
|
|
|
$ |
5,740 |
|
|
|
$ |
28,846 |
|
|
|
$ |
18,366 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP total operating expense |
|
$ |
44,120 |
|
|
|
$ |
32,032 |
|
|
|
$ |
138,127 |
|
|
|
$ |
104,430 |
|
|
Stock-based compensation expense |
|
|
(4,724 |
) |
|
|
|
(6,194 |
) |
|
|
|
(17,176 |
) |
|
|
|
(21,184 |
) |
|
Non-GAAP total operating expense |
|
$ |
39,396 |
|
|
|
$ |
25,838 |
|
|
|
$ |
120,951 |
|
|
|
$ |
83,246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
